Geron is a commercial-stage biopharmaceutical company with a first-in-class
telomerase inhibitor that is approved in the United States for the treatment of certain adult
patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia.
As the sole company with an oligonucleotide telomerase inhibitor approved by the
FDA, we are exploring its potential across multiple hematologic malignancies. We are conducting
a pivotal Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as
well as studies in other myeloid hematologic malignancies. Inhibiting telomerase activity, which
is increased in malignant stem and progenitor cells in the bone marrow, aims to reduce
proliferation and induce death of malignant cells.
At Geron, we are united by a shared purpose: Every individual in every role can
meaningfully contribute to our mission to change lives by changing the course of blood cancer.